Establishment of Monoclonal Antibody PMab-202 Against Horse Podoplanin

Yoshikazu Furusawa, Shinji Yamada, Shunsuke Itai, Masato Sano, Takuro Nakamura, Miyuki Yanaka, Saori Handa, Takuya Mizuno, Ken Maeda, Masato Fukui, Hiroyuki Harada, Mika K. Kaneko, Yukinari Kato

研究成果: ジャーナルへの寄稿学術論文査読

30 被引用数 (Scopus)

抄録

Podoplanin (PDPN), a type I transmembrane glycoprotein, is expressed in several body tissues, including podocytes of renal glomerulus, type I alveolar cells of lung, and lymphatic endothelial cells. PDPN activates platelet aggregation by binding to C-type lectin-like receptor-2 (CLEC-2) presented on platelets. Monoclonal antibodies (mAbs) against human-, mouse-, rat-, rabbit-, dog-, bovine-, and cat-PDPN have already been established. However, anti-horse PDPN mAbs have not yet been developed. In this study, we immunized mice with synthetic horse PDPN peptides and developed anti-horse PDPN mAbs. One of the established mAbs, PMab-202 (IgG1, kappa), was specifically able to detect horse PDPN in Chinese hamster ovary/horse PDPN (CHO/horPDPN) cells in flow cytometry experiments. PMab-202 was also able to detect endogenous horse PDPN expressed in and a horse kidney cell line, FHK-Tcl3.1, in flow cytometry and Western blot analyses. PMab-202 is expected to prove useful in investigating the function of horse PDPN.

本文言語英語
ページ(範囲)233-237
ページ数5
ジャーナルMonoclonal Antibodies in Immunodiagnosis and Immunotherapy
37
5
DOI
出版ステータス出版済み - 2018 11月

フィンガープリント

「Establishment of Monoclonal Antibody PMab-202 Against Horse Podoplanin」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル